Summarized by Masters of Longevity from PR Newswire.
Company filed FDA and EMA applications after Phase 3 HIBISCUS results.
Key Takeaways
- HIBISCUS showed a 27% VOC reduction versus placebo.
- Trial enrolled adolescents and adults aged 12 years and older.
- Findings are from a randomized trial and are not causal proof.
